Hologic Target of Unusually Large Options Trading (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) saw some unusual options trading on Monday. Investors bought 3,509 put options on the company. This represents an increase of approximately 207% compared to the average daily volume of 1,144 put options.

Institutional Investors Weigh In On Hologic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its stake in Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares during the period. HBK Investments L P purchased a new stake in Hologic in the fourth quarter worth $625,716,000. Geode Capital Management LLC grew its stake in Hologic by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 5,919,013 shares of the medical equipment provider’s stock worth $439,228,000 after purchasing an additional 22,019 shares during the period. Victory Capital Management Inc. grew its stake in Hologic by 2.6% in the fourth quarter. Victory Capital Management Inc. now owns 5,609,912 shares of the medical equipment provider’s stock worth $417,882,000 after purchasing an additional 139,867 shares during the period. Finally, FIL Ltd grew its stake in Hologic by 10,317.8% in the fourth quarter. FIL Ltd now owns 5,227,433 shares of the medical equipment provider’s stock worth $389,391,000 after purchasing an additional 5,177,255 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic News Summary

Here are the key news stories impacting Hologic this week:

• Positive Sentiment: The company confirmed a go‑private acquisition by Blackstone/TPG and announced that CEO Steve MacMillan will retire upon close — this buyout typically implies a takeover premium for public shareholders and explains upward pressure on the share price. Business Wire: Hologic CEO to Retire Upon Close of Go‑Private Transaction MarketWatch: Hologic Chairman, CEO Steve MacMillan to Step Down
• Positive Sentiment: Multiple outlets report the CEO retirement is tied to the private equity deal (expected close triggers executive transition) — that reduces surprise governance risk at close and clarifies the exit path for public holders. MassDevice: Hologic CEO MacMillan to retire following private equity acquisition TipRanks: CEO Retirement Announced Amid Buyout
• Neutral Sentiment: Analysts and index watchers are discussing S&P 500 roster changes tied to the acquisition — Hologic’s pending take‑private opens a slot in the index; names like Marvell, Alnylam and Veeva are cited as potential replacements, which matters to index‑tracking flows but is one‑step removed from HOLX’s buyout valuation. MarketWatch: S&P 500 change may be imminent Morningstar: Stock joining the S&P 500
• Negative Sentiment: Traders showed unusually large put buying today (roughly a 207% increase vs. average daily put volume), signaling either hedging ahead of deal uncertainty or speculative downside bets — increased puts can add short‑term volatility and reflect some investor caution. (options flow report)

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HOLX shares. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and decreased their target price for the company from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Two investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Price Performance

Shares of Hologic stock opened at $76.01 on Tuesday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The company has a market cap of $16.97 billion, a PE ratio of 31.67, a P/E/G ratio of 2.24 and a beta of 0.70. The business has a 50 day moving average of $75.29 and a 200 day moving average of $73.77. Hologic has a 52 week low of $51.90 and a 52 week high of $76.07.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.87 earnings per share. As a group, equities research analysts forecast that Hologic will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.